In 2022, one in eight people in the world, were living with obesity accounting a total of 2.5 billion adults aged 18 years and older were overweight, including nearly 900 million adults who were living with obesity
Wang D, Wei Y, Pagliassotti MJ
NCBI Bookshelf NBK5274
After reviewing clinical trial data, post-marketing surveillance reports, and real-world evidence across millions of prescriptions, the EMA concluded in 2024 that the available evidence does not support a causal association between GLP1 receptor agonists and suicidal or self-injurious behavior
These therapies display higher efficiency compared to classical senolytic drugs (BCL-2 or tyrosine kinase inhibitors) but for some of them, such as NA + /K + ATPase inhibitors, clinical development could be complex in the light of strong cardiotoxicity associated with this class of molecules
in patients with diabetics with gastroparesis, optimization of glycemic control must also be achieved